16th May 2019: Antibody drug conjugates (ADCs) are the most important bio-pharmaceutical drugs that are highly potent and are designed to treat cancer. These conjugates intend to aim and destroy only the cancer cells while keeping healthy cells unaffected. ADCs are the most complex molecules that are majorly composed of an antibody that is linked to a biologically active cytotoxic payload or drug.
Technological advancements to spur the demand for antibody drug conjugates
Cleavable and non-cleavable linkers are the two types of technology in the antibody drug conjugates market and are the most prime technologies used to link cytotoxic anticancer agent’s payload. It has been projected that cleavable linkers will foresee the fastest development during the estimated time span due to the vast number of products in the pipeline and the extensive usage of linkers.
The market witnessed the launch of two new Pfizer’s products in 2017, Bespona and Mylotarg that were accepted for the usage in the developed countries and both these products contained cleavable linkers. Additionally, Adcetrics and Kadcyla are two of the best-selling ADcs that comprise cleavable and non-cleavable linkers. The World Health Organization (WHO) stated that in 2017 the most common types of cancer were lung cancer, breast cancer, prostrate cancer, stomach cancer, skin cancer, and colorectal cancer. Rising cases of these cancers is one of the major dynamic that is surging the growth of the market.
Antibody drug conjugates are surging in the developed economies
Cleavable linkers are majorly accelerating in North America region and its countries due to the tremendous demand for Mylotarg. Furthermore, this region is anticipated to witness the fastest growth over the forecast period because most of the cleavable and non-cleavable linkers are being highly developed in the U.S. Europe is also expected to continue its dominance due to the massive usage of ADCs coupled with immense patient awareness and well-established infrastructure of healthcare.
Market Insights
Some of the major key players that are operating and helping the antibody drug conjugates market to accelerate are Pharmaceutical Company Limited; Seattle Genetics Inc.; F. Hoffmann-La Roche Ltd.; Takeda Pfizer Inc.; and AbbVie Inc.
No comments:
Post a Comment